Canbridge Pharmaceuticals (HKSE:01228) 3-Year Dividend Growth Rate : 0.00% (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Canbridge Pharmaceuticals 3-Year Dividend Growth Rate?

Canbridge Pharmaceuticals's Dividends per Share for the six months ended in Jun. 2024 was HK$0.00.

The historical rank and industry rank for Canbridge Pharmaceuticals's 3-Year Dividend Growth Rate or its related term are showing as below:

HKSE:01228's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 8.65
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Canbridge Pharmaceuticals's Dividend Payout Ratio for the six months ended in Jun. 2024 was 0.00. As of today, Canbridge Pharmaceuticals's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Canbridge Pharmaceuticals's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Canbridge Pharmaceuticals's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Canbridge Pharmaceuticals's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Canbridge Pharmaceuticals's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Canbridge Pharmaceuticals's 3-Year Dividend Growth Rate falls into.

Save Embed

;

Save Embed

;

Canbridge Pharmaceuticals 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Canbridge Pharmaceuticals (HKSE:01228) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Canbridge Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Jun. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Jun. 2024 )	/	EPS without NRI (Q: Jun. 2024 )
	=	0	/	-0.624
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Canbridge Pharmaceuticals 3-Year Dividend Growth Rate Related Terms>

Canbridge Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Canbridge Pharmaceuticals Inc (HKSE:01228) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

Building 21, No. 388 Xinping Street, Unit 18, 6th Floor, Suzhou Industrial Park, Suzhou, CHN

Website

https://www.canbridgepharma.com

Canbridge Pharmaceuticals Inc is a biopharmaceutical company. It is committed to the research, development, and commercialization of biotech therapies targeting rare diseases and rare oncology. The company's core product in the rare oncology area CAN008, is a glycosylated CD95-Fc fusion protein being developed for the treatment of glioblastoma multiforme (GBM). In the rare disease area, the company have seven biologics and small molecules products and product candidates for the treatment of Hunter Syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, and rare cholestatic liver diseases including ALGS, PFIC and BA. Its pipeline consists of biologics, small molecules, and gene therapy solutions and 13 drugs.

Executives

Qiming Corporate Gp Iv, Ltd.	2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p.	2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p.	2101 Beneficial owner
Xue James Qun	2101 Beneficial owner
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Athos Capital Limited	2102 Investment manager
Moskey Matthew Love	2201 Interest of corporation controlled by you
Schulte-hillen Friedrich Bela	2201 Interest of corporation controlled by you
Athos Asia Event Driven Master Fund	2101 Beneficial owner
Ctx Pharma Holdings Limited	2101 Beneficial owner
Kolchinsky Anna Inge Leonore Haas	2202 Interest of your spouse
Kolchinsky Peter	2305 Beneficiary of a trust
Ra Capital Management, L.p.	2102 Investment manager
Ra Capital Healthcare Fund Gp, Llc	2201 Interest of corporation controlled by you
Ra Capital Healthcare Fund, L.p.	2101 Beneficial owner

Canbridge Pharmaceuticals Headlines

No Headlines